Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189782 | 1.00 | RORC (0.40) | RORCNR1I2CYP11B1CYP11B2CETP | |
| SCHEMBL4188271 | 1.00 | RORC (0.40) | RORCNR1I2CYP11B1CYP11B2CETP | |
| SCHEMBL4184766 | 0.91 | MAPT (0.45) | CYP11B1CYP11B2CCR2KCNH2SUCNR1 | |
| SCHEMBL4185760 | 0.91 | MAPT (0.45) | CYP11B1CYP11B2CCR2KCNH2SUCNR1 | |
| SCHEMBL4453542 | 0.91 | MAPT (0.45) | CYP11B1CYP11B2CCR2KCNH2SUCNR1 | |
| SCHEMBL13625387 | 0.90 | CYP11B1 (0.41) | RORCCYP11B1CYP11B2CETPCCR2 | |
| SCHEMBL4190731 | 0.90 | SUCNR1 (0.38) | RORCNR1I2CYP11B1CYP11B2CCR2 | |
| SCHEMBL4194972 | 0.90 | SUCNR1 (0.38) | RORCNR1I2CYP11B1CYP11B2CCR2 | |
| SCHEMBL4185981 | 0.90 | SUCNR1 (0.38) | RORCNR1I2CYP11B1CYP11B2CCR2 | |
| SCHEMBL4454859 | 0.87 | CYP11B1 (0.36) | CYP11B1CYP11B2CCR2KCNH2SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| WO-2008048540-A2 | 2-HYDROXY-2-PHENYL/THIOPHENYL PROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | SHBG, AR, FSHR | RORC 2145/4885NR1I2 332/4885CYP11B1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.